



## Tobin P. Sullivan

PARTNER

617-248-4742 | [tsullivan@choate.com](mailto:tsullivan@choate.com)

Tobin Sullivan is a versatile corporate and securities attorney who counsels growth equity and venture capital investors and growing life sciences and technology companies, ranging from start-ups to pre-IPO companies to global public companies, on a wide range of transactional and corporate law matters. With extensive experience representing investors in growth equity, venture capital and cross-over financings for life sciences, biotech, healthcare and healthIT companies, he is described by clients as a highly responsive, strategic thinker who balances his strong market knowledge with practical business advice.

Tobin provides general corporate guidance on a variety of business matters, including venture capital and growth equity financings, national and cross-border mergers and acquisitions, corporate governance matters, public company reporting, and SEC compliance. His clients have included Bain Capital Life Sciences, Surveyor Capital (a Citadel company), Andreessen Horowitz (a16z), Sectoral Asset Management, Transformation Capital, Pegasystems, Forrester Research, Riverside Partners, Summit Partners, and M/C Partners.

### Focus Areas

Private Equity and M&A

Buyouts, Growth  
Equity and M&A

Life Sciences and  
Technology

### Recognition

- *Chambers USA* (2025-2026)
- *Boston Magazine Top Lawyer* (2021)
- *Massachusetts Super Lawyers: Rising Star* (2016-2022)
- *The Legal 500* (2021-2025)
- *LMG Life Sciences: Rising Star* (2025)
- *Massachusetts Super Lawyers*

### Representative Engagements

#### Private Equity & Venture Capital Engagements

- **Bain Capital Life Sciences'** growth equity investments in biotech companies, including:
  - **Arcutis Biotherapeutics** (Nasdaq: ARQT) – \$95 million Series C financing
  - **Aptinyx** (Nasdaq: APTX) – \$70 million Series B financing
  - **Atea Pharmaceuticals** (Nasdaq: AVIR) – \$215 million Series D financing
  - **Jnana Therapeutics** – \$107 million Series C financing
  - **JenaValve Technology** – \$100 million Series C financing

- **Transformation Capital's** growth equity investments in Health IT and healthcare services companies, including:
  - **Alaffia Health** – \$55 million Series B financing
  - **SmarterDx** – \$50 million Series B financing
  - **Rad AI** – \$60 million Series C financing
- **Surveyor Capital's** growth equity and cross-over investments in life sciences companies, including:
  - **VelosBio** – \$137 million Series B financing
  - **Acrivon Therapeutics** (*Nasdaq: ACRV*) – \$100 million Series B financing
  - **Allogene** (*Nasdaq: ALLO*) – \$120 million private financing
  - **SpringWorks Therapeutics** (*Nasdaq: SWTX*) – \$125 million Series B financing
  - **ElevateBio** – \$170 million Series B financing
  - **Pliant Therapeutics** – \$100 million Series C financing
- **Andreessen Horowitz's** venture capital and growth equity investments in bio + health, consumer and enterprise technology companies
- **Summit Partners' growth equity investments** in software and technology companies
- **The Chernin Group (TCG)'s** growth equity investments, including:
  - **The Pro's Closet**
  - **Surflin**
  - **Epic Gardening**
- **Sectoral Asset Management's** growth equity investments in therapeutics and medical device companies, including:
  - **Apnimed** – \$62.5 million Series C financing
  - **Apellis Pharmaceuticals** (*Nasdaq: APLS*) – \$60 million Series E financing
  - **LENZ Therapeutics** – \$83.5 million Series B financing
- **M/C Partners' carve-out acquisition** of Ascend Technologies from West Monroe Partners
- **Riverside Partners' majority investment** in 3Play Media

## Business & Technology Engagements

- **Creation Technologies' acquisition** of IEC Electronics Corp. (*Nasdaq: IEC*)
- **Datawatch Corporation's** (*Nasdaq: DWCH*) \$176 million merger with Altair Engineering (*Nasdaq: ALTR*)
- **Eximity Inc.'s** \$90 million growth equity investment from Great Hill Partners
- General counsel to satellite broadband company, including advising on its \$1+ billion equity financing led by SoftBank
- **BioRx's** \$350 million sale to Diplomat Pharmacy (*NYSE: DPLO*)
- **Cyteir Therapeutics' equity financing** led by Venrock Partners, Celgene, Lightstone Ventures, and DROIA Oncology Venture
- **Cosman Medical's** sale to Boston Scientific (*NYSE: BSX*)
- FP Resources USA Inc.'s take-private acquisition of **The First Marblehead Corporation** (*NYSE: FMD*)
- **Pegasystems Inc.'s** (*Nasdaq: PEGA*) \$600 million 144A convertible note financing

## Publications and Presentations

- ["Funding Gap for Life Science Companies Is Still a Problem," co-author, Life Sciences Law360, September 2013](#)

## Professional & Community Involvement

- Corporate pro bono work for the Center for Women & Enterprise
- Pro bono clients from the Lawyer's Clearinghouse and Massachusetts Legal Clinic for the Homeless
- Member of the Boston Bar and American Bar Associations
- Member of Choate's Hiring Committee

## Education & Credentials

- Northeastern University School of Law, JD (2012) *Staff Member, Northeastern University Law Journal*
- Cornell University, BS (2007)

## Admissions

- Massachusetts
- Maine